Opinion: Chemo-Free Regimens Join Crowded Field of Potential Therapies for Osimertinib-Resistant NSCLC Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC. Data from these trials were presented at #ELCC25 by Dr Xiuning Le of @mdanderson.bsky.social, Dr Ross Soo, and Dr Myung-Ju Ahn. shorturl.at/j6WMT

Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy - ILCN.org (ILCN/WCLC) Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress.

#ELCC25 Recap: Drs. Chih-Hsin Yang and Pérol break down the latest findings from the MARIPOSA trial.

Learn more in ILCN: bit.ly/44uMiwW

CCTG BR.31 Data Show Adjuvant Durvalumab Does Not Alter Relapse Frequency or Patterns in Resected NSCLC Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

CCTG BR.31 Data Show Adjuvant Durvalumab Does Not Alter Relapse Frequency or Patterns in Resected NSCLC
#ELCC25 #NSCLC #LCSM
www.onclive.com/view/cctg-br...

ELCC 2025: Insights and Review of the Data | IASLC In this episode of Lung Cancer Considered, host Dr. Narjust Florez and Dr. Corey Langer discuss data presented at the recent European Lung Cancer Congress (ELCC ...

On the new episode of #LungCancerConsidered @narjustflorezmd.bsky.social & Dr. Corey Langer discuss major updates from #ELCC25. These updates include MARIPOSA and ORCHARD & SOHO-01 trials, plus strategies to address treatment toxicity.

🎧 Listen here: bit.ly/LCC25ELCC

#ELCC25

Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.

Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC @mdanderson.bsky.social
@myesmo.bsky.social #ELCC25 #lcsm #oncology
www.onclive.com/view/osimert...

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC #ELCC25 #lcsm #oncology www.onclive.com/view/daraxon...

Interested in the latest developments in #LungCancer? Check out the most recent #ESMODailyReporter articles from #ELCC25 and stay up-to-date with the cutting-edge developments in oncology

🔗 ow.ly/7I3b50VuCoz

Triplet May Provide Chemo-Free Option for EGFR-Mutant NSCLC The combination of amivantamab, lazertinib, and bevacizumab can produce durable anti-tumor activity in patients with EGFR-mutant NSCLC that has progressed on a third-generation EGFR TKI.

Amivantamab, lazertinib, & bevacizumab can produce durable anti-tumor activity in patients with EGFRm NSCLC that has progressed on a third-generation EGFR TKI, according to research presented at #ELCC25 by Dr Ross Soo of National University Cancer Institute, Singapore. #lcsm shorturl.at/fHyYa

Osimertinib After Definitive Chemoradiation Is New SOC for Unresectable Stage III EGFR+ NSCLC Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.

Osimertinib After Definitive Chemoradiation Is New SOC for Unresectable Stage III EGFR+ NSCLC @ramalingammd.bsky.social @winshipatemory.bsky.social @myesmo.bsky.social #ELCC25 #lcsm #oncology www.onclive.com/view/osimert...

Highlights from ELCC Day 3 - OncoDaily Highlights from ELCC Day 3 / Alessandra Dodi, Alfredo Addeo, Amol Akhade, Antonio Calles, cancer, ELCC, ELCC 2025, ELCC25, Eric Halioua, ESMO, Giannis

Highlights from ELCC Day 3

@suyogcancer.bsky.social
@drgreeklungcancer.bsky.social
@drjnaidoo.bsky.social

oncodaily.com/societies/26...

#Cancer #ELCC #ELCC2025 #ELCC25 #ESMO #LungCancer #NSCLC #OncoDaily #Oncology #ThoracicOncology #Medicine #Health

Quick shout-out on these two collaborative networks (#BOLERO
and #COALA) during my presentation at #ELCC25.

Looking forward to advancing basic and translational research on #BRAF-mutant #NSCLC and other oncogene-driven #NSCLC.

x.com/JulienMazier...

Pembrolizumab Plus CRT Provides Durable Tumor Control in NSCLC Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

Pembrolizumab plus CRT provided long-term tumor control in patients with previously untreated, unresectable, stage III NSCLC in the KEYNOTE-799 trial. Final results were presented at #ELCC25 by Dr Martin Reck of Lung Clinic Grosshansdorf. #lcsm shorturl.at/wAZgC

🫁 #ELCC25
Preventing Moderate to Severe Dermatologic Adverse Events in 1st Line EGFR-Mutant Advanced #NSCLC Treated with Amivantamab Plus Lazertinib:
➡️ Early Success of the COCOON Study, nice results presented at ELCC25 by Prof. Nicolas Girard @institutcurie.bsky.social

#Oncsky

New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer.

Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM

Joseph Deasy, Sarat Chandarlapaty, and Marc Ladanyi presented #lungcancer research at #ELCC25 @myesmo.bsky.social. Learn more about RRAS and RRAS2 hotspot mutations as drivers in lung cancer, mechanisms of resistance of ADC, and artificial intelligence in radiation treatment planning. bit.ly/4jbM4Pr

Addition of Savolitinib Can Reverse Osimertinib Resistance in Advanced NSCLC Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

Adding savolitinib to osimertinib induced durable responses in pts w/ EGFRm advanced NSCLC whose disease had progressed on 1st-line osimertinib. These results were presented at #ELCC25 by Dr Myung-Ju Ahn. Written by @liamdjournalist.bsky.social. #lcsm shorturl.at/pnYcZ

In the final analysis of the KEYNOTE-799 trial, pembrolizumab plus concurrent chemoradiation showed "robust and durable anti-tumor activity" in unresectable, locally advanced NSCLC, with no new safety signals, reported Dr Martin Reck of Lung Clinic Grosshansdorf at #ELCC25. #lcsm

Predicting surgical complexity following neo-adjuvant chemoIO

Single centre 🇬🇧 study

👉 43% defined as complex

🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%

#ELCC25

Osimertinib after definitive chemoradiotherapy is a "new standard of care" in unresectable, stage III, EGFR-mutant NSCLC, reported @ramalingammd.bsky.social of @winshipatemory.bsky.social in an updated analysis of the LAURA study presented at #ELCC25. #ELCC2025 #lcsm

LAURA OS update (LBA4)
👉 Now 31% maturity

❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant

💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD

#ELCC25

Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable Responses in KRAS G12C–Mutated NSCLC Fulzerasib plus cetuximab elicited deep efficacy in patients with KRAS G12C–mutated NSCLC enrolled in the phase 2 KROCUS study.

Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable Responses in KRAS G12C–Mutated NSCLC #ELCC25 #lcsm www.onclive.com/view/frontli...

Adagrasib Combo Continues to Show Efficacy in KRAS G12C–Mutated NSCLC and PD-L1 ≥50% Adagrasib plus pembrolizumab continued to show promising efficacy in patients with KRAS G12C–mutated NSCLC and PD-L1 TPS of 50% or higher.

Adagrasib Combo Continues to Show Efficacy in KRAS G12C–Mutated #NSCLC and PD-L1 ≥50% #ELCC25

www.onclive.com/view/adagras...

SC pembrolizumab is non-inferior to IV pembrolizumab for newly diagnosed, stage IV NSCLC, according to phase 3 data presented at #ELCC25 by Dr Enriqueta Felip of @vhio.bsky.social. Written by @alanlyssmd.bsky.social #lcsm shorturl.at/YGNLR

🫁 #ELCC25
Prof. Nicolas Girard @institutcurie.bsky.social presented positive results from 2 expansion cohorts of the SOHO-01 study, confirming initial findings and supporting continued clinical development of a new HER2-targeted therapy treatment in #NSCLC
👉 cslide.ctimeetingtech.com/coasis_21204...

🫁 #ELCC25
Precision medicine in #NSCLC, patient quality of life, real-life data, thymus cancer: Find out Institut Curie's presentations at the European #LungCancer Congress 2025

👉 institut-curie.org/news/institu...

#OncSky

Amivantamab, lazertinib, & bevacizumab showed "durable anti-tumor activity" in pts w/ advanced NSCLC whose disease had progressed on a 3rd-gen EGFR TKI, said Dr Ross Soo of the National University Cancer Institute, Singapore. He presented data from the phase 2 ETOP AMAZE-lung trial at #ELCC25. #lcsm

Taletrectinib improves outcomes compared to crizotinib in TKI-naive patients with ROS1-positive NSCLC, according to research presented at #ELCC25 by Dr. Misako Nagasaka of the University of California Irvine School of Medicine. #ELCC2025 #lcsm

3) KROCUS single arm phase 2 showing magnificent activity with fulverasib + cetuximab in 1st line nsclc, pdl1 agnostic. Very important and unexpected non IO option. It feels like egfr antibodies maybe offering something different to TKIs here. Again congrats+++ to all investigators #ELCC25

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

Subcutaneous pembrolizumab is noninferior to intravenous pembro in treatment-naive metastatic NSCLC, according to results presented at #ELCC25 by Dr. Enriqueta Felip of @vallhebroncampus.bsky.social. #ELCC2025 #lcsm